At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
Vinfluninedrug
Likely dose
Vinflunine 320mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Vinflunine for Carcinoma, Small Cell and Lung Cancer. Completed, enrolled 51 participants across 3 sites.
Detailed Summary
This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer. The purpose of this research trial is to study the effectiveness of vinflunine in patients with relapsed extensive small cell lung cancer, evaluate the toxicity, and evaluate how long the response to this drug lasts.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Small Cell, Lung Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedJan 2006
Primary CompletionMay 2009
Study CompletionNov 2009
TodayJul 2026
First PostedJan 31, 2006
Enrollment StartJan 1, 2006
Primary CompletionMay 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.4 years ago
Interventions
Vinfluninedrug
320mg/m2 every 21 days as a 15-20 minute infusion